Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical trials of the synthetic peptide Chrysalin have been discontinued by the company OrthoLogic after no significant difference was found in the incidence of adverse events between the Chrysalin and placebo groups.
Subscribe to our email newsletter
Chrysalin was being developed to accelerate bone healing in the case of wrist fractures. The study was to test the safety and efficacy of the doses of Chrysalin on the rate of healing in adults with unstable and/or displaced wrist fractures.
Phase III trials conducted earlier in the year with Chysalin, had also failed to produce the desired results.
OrthoLogic said the interim analysis would continue, and any significant findings would be disclosed as appropriate.
Despite the negative results, Dr Randolph Steer President of OrthoLogic said “We intend to proceed with our planned approach to the US and European regulatory authorities to discuss pathways forward for TP508 in fracture repair.”